SUBSCRIBE
SUBSCRIBE
News   Drug Development

Exelixis, Inc. Drug Shows Promise in Brain Cancer-Study

May 15, 2009 | 
1 min read
Reuters -- An experimental drug being developed by Exelixis Inc and Bristol-Myers Squibb Co was shown to shrink brain tumors in some patients, according to interim results from a mid-stage study of the drug, known as XL184.
Clinical research Phase II Phase III
Exelixis, Inc.
MORE ON THIS TOPIC
Job interview, recruitment concepts. Row of chairs with one odd one out. Job opportunity. Blue chair in spotlight. Business leadership. 3D Rendering
FDA
From Expertise to Empty Chairs: The FDA’s Self-Inflicted Crisis
July 23, 2025
 · 
7 min read
 · 
Lori Ellis
ASD autism neurodevelopmental spectrum disorder, deficits in social communication and interaction, brain with impairment, hypersensitivity and abnormalities
GLP-1
GLP-1s Could Protect Against Neurodegeneration, Study Finds
July 23, 2025
 · 
2 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH ECLIPSEBIO
Why Countries Are Racing To Build mRNA Factories While America Hesitates on Next-Gen Vaccines
July 22, 2025
 · 
1 min read
 · 
Lori Ellis
Illustration of man waving big white flag, surreal abstract concept
Duchenne muscular dystrophy
Sarepta Concedes to FDA Request, Suspends US Shipments of Elevidys
July 22, 2025
 · 
2 min read
 · 
Tristan Manalac